Tumor Gene Expression Profiling in Women with Breast CancerTest Category: Prognostic | Zendy

Cecelia Bellcross | Zendy; W. David Dotson | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Tumor Gene Expression Profiling in Women with Breast CancerTest Category: Prognostic

Author(s) -

Cecelia Bellcross,

W. David Dotson

Publication year - 2010

Publication title -

plos currents

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.282

H-Index - 49

ISSN - 2157-3999

DOI - 10.1371/currents.rrn1178

Subject(s) - medicine , breast cancer , tamoxifen , oncology , estrogen receptor , gene expression profiling , oestrogen receptor , disease , chemotherapy , bioinformatics , gene expression , gene , cancer , biochemistry , biology , chemistry

Differences in the expression of specific genes within breast tumors have been associated with risk of recurrence after treatment. Most women with Stage I or II node-negative breast cancer (especially when estrogen-receptor positive and treated with tamoxifen) remain disease-free at 10 years. Information on risk of recurrence could help identify women most likely to benefit from chemotherapy. Several clinically available gene expression profiles (GEP) provide "recurrence risk scores" that are intended to supplement information used by clinicians and patients in treatment decision-making.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research